 Continuous tumor-infiltrating lymphocytes treatment advanced melanoma national biotherapy study group trial Melanoma metastases patients purpose tumor-infiltrating lymphocytes TIL Tumor tissue cell suspensions repeated exposure antigen monoclonal antibody MoAb Initial growth success cultures Efforts cultures therapeutic TIL early cultures vivo therapy mean days sufficient TIL treatment Therapy cyclophosphamide day continuous infusion days mean day Patients infusion Median patient age years age Sixty-seven percent patients men Performance status patients percent patients liver metastases usual toxicities Response rate patients confidence interval complete response cells partial responses cells patients TIL response authors treatment plan difficult costly effective minority patients Overall clinical results superior regimens